{
  "slug": "evolvere-biosciences",
  "name": "Evolvere BioSciences",
  "yc_id": 29475,
  "batch": "Summer 2024",
  "website": "https://www.evolverebiosciences.com/",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:29:58.326792",
    "website": "https://www.evolverebiosciences.com/",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 3225.13,
      "final_url": "https://evolverebiosciences.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:30:01.551932"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "evolverebiosciences.com",
      "registrar": "IONOS SE",
      "creation_date": "2021-08-26T16:36:54",
      "expiration_date": "2026-08-26T16:36:54",
      "domain_age_days": 1512,
      "domain_age_years": 4.1,
      "name_servers": [
        "NS1034.UI-DNS.BIZ",
        "NS1079.UI-DNS.DE",
        "NS1124.UI-DNS.ORG",
        "NS1126.UI-DNS.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": true,
      "referrer_policy": true,
      "security_score": 66,
      "server": "cloudflare"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:20.623357",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "google/gemini-2.0-flash-001",
    "enriched_at": "2025-10-17T12:42:16.644025",
    "status": "success",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Increasing antibiotic resistance",
        "Growing investment in novel antibiotic development",
        "Personalized medicine approaches to infection treatment"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary computational models and co-evolutionary protein-protein interaction technology create a strong technological moat.",
      "differentiation": "Designing antibiotics that outpace bacterial evolution, targeting specific pathogens without harming beneficial microbes.",
      "competitive_advantages": [
        "Potential for longer-lasting efficacy compared to traditional antibiotics",
        "Reduced risk of disrupting the microbiome"
      ],
      "competitive_vulnerabilities": [
        "Regulatory hurdles for novel antibiotics are high",
        "Requires significant computational and biological validation"
      ]
    },
    "business_model": {
      "revenue_model": "Likely licensing or direct sales of novel antibiotic compounds.",
      "scalability": "medium",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Successful preclinical trials",
        "Partnerships with pharmaceutical companies"
      ],
      "growth_bottlenecks": [
        "Securing funding for clinical trials",
        "Demonstrating superior efficacy and safety compared to existing treatments"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "medium",
      "overall_risk_score": 7,
      "key_risks": [
        "Failure to achieve desired efficacy in clinical trials",
        "Bacterial resistance developing to the new antibiotics",
        "Competition from established pharmaceutical companies"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Addresses a critical unmet need in global healthcare",
        "Novel approach with potential for significant impact",
        "Strong computational biology foundation"
      ],
      "concerns": [
        "High regulatory hurdles and development costs",
        "Long time to market"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Achaogen (acquired)",
        "Paratek Pharmaceuticals"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Focus on preclinical validation and IND-enabling studies",
        "Secure strategic partnerships with pharmaceutical companies"
      ],
      "expansion_opportunities": [
        "Expand the platform to address other infectious diseases",
        "Develop companion diagnostics for personalized antibiotic treatment"
      ]
    },
    "tokens_used": {
      "prompt": 712,
      "completion": 632,
      "total": 1344,
      "estimated_cost": 0.000243
    }
  },
  "phase8_complete": true
}